Original articleResponse to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases
References (26)
- et al.
Surgery for pulmonary metastasis: a 20-year experience
Ann Thorac Surg
(1984) - et al.
Analysis of prognostic factors in patients undergoing resection of pulmonary metastases from soft tissue sarcomas
J Thorac Cardiovasc Surg
(1984) - et al.
Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease
J Thorac Cardiovasc Surg
(1971) - et al.
Metastasectomy for soft tissue sarcoma: further evidence for efficacy and prognostic indicator
J Thorac Cardiovasc Surg
(1989) - et al.
Comparisons of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas
Ann Thorac Surg
(1986) - et al.
Randomized clinical trial of preoperative chemotherapy and postoperative adjuvant chemotherapy with cisplatin, vindesin, and Adriamycin for carcinoma of the esophagus
J Thorac Cardiovasc Surg
(1988) - et al.
Pulmonary resection for metastatic sarcoma
Am J Surg
(1980) - et al.
Pulmonary resection in children with metastatic osteogenic sarcoma: improved survival with surgery, chemotherapy, and irradiation
J Thorac Cardiovasc Surg
(1978) - et al.
Pulmonary resection for metastatic non-osteogenic sarcoma
Cancer
(1979) - et al.
Multiple pulmonary metastasectomies in patients with soft tissue sarcoma
Arch Surg
(1986)
Criteria for resection of sarcoma metastatic to the lung
Cancer Chemother Rep
The chemotherapy of adult soft tissue sarcomas in adults
Randomized comparison of Adriamycin regimens for treatment of metastatic soft tissue sarcomas [Abstract]
Cited by (77)
Treating metastatic sarcomas locally: A paradoxe, a rationale, an evidence?
2015, Critical Reviews in Oncology/HematologyCitation Excerpt :On the other hand, chemotherapy given before surgery for patients with short DFI and large tumor bulk, may help assess tumor kinetics, tumor response [109] and select for further treatments [110–112]. Old data before the era of ifosfamid did not support the use of perioperative chemotherapy [113] and the EORTC-STBSG 62933 trial randomizing between chemotherapy followed by metastasectomy and metastasectomy alone failed because of slow accrual. Canter et al. compared 85 metastatic extremity soft-tissue sarcoma patients undergoing pulmonary resection alone with 53 patients undergoing surgery and perioperative chemotherapy [39].
Multimodality therapy for advanced or metastatic sarcoma
2013, Current Problems in CancerPulmonary Metastasectomy for Soft Tissue Sarcoma
2012, Surgical Oncology Clinics of North AmericaCitation Excerpt :When given as a neoadjuvant for patients who are potential candidates for PM, chemotherapy response rate of 30% to 50% with complete clinical responses of 12% to 21% have been reported.88,93 Lanza and colleagues93 examined 24 patients undergoing neoadjuvant chemotherapy followed by PM. A complete radiographic response was seen in 21%, 29% had a partial response, and 50% had no change or disease progression.
Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival
2011, Annals of Thoracic SurgeryProgression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients
2011, Journal of the American College of SurgeonsCitation Excerpt :Briccoli and colleagues22 found no difference in survival between patients with osteosarcoma undergoing resection of pulmonary metastases who underwent neoadjuvant chemotherapy and those who did not, but again, progression when on neoadjuvant chemotherapy was not evaluated. In a study by Lanza and colleagues23 conducted from 1979 to 1988, progression when on neoadjuvant chemotherapy was not shown to influence long-term survival of 26 patients undergoing sarcomatous pulmonary metastasectomy. Lastly, in a study by Huth and colleagues24 published in 1980, a select group of 21 patients were chosen to receive neoadjuvant chemotherapy based on tumor doubling time.